Biotron Limited announced that preliminary analyses of data from the BIT225-011 Phase 2 clinical trial of the Company’s lead antiviral drug BIT225 indicate that the primary objectives of the trial have been met.
This longitudinal, open-label Phase 2 trial was designed to characterise the effect of BIT225 (200 mg, once daily) added to ongoing, suppressive standard of care antiretroviral therapy (cART) for twelve weeks in twenty HIV-1 infected, treatment-experienced participants who had achieved only partial immune reconstitution.
The primary objectives of the trial were to evaluate the safety and tolerability of BIT225 in this patient population, as well as to determine the impact of the addition of BIT225 to cART on immune activation, inflammation and viral markers.
Access the full announcement here.
Related HIV and Co-Infections News
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.